Literature DB >> 9462205

Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.

A E Berstad1, J G Hatlebakk, H Maartmann-Moe, A Berstad, P Brandtzaeg.   

Abstract

BACKGROUND: Helicobacter pylori gastritis may spread proximally in the stomach during profound acid inhibition. AIMS: To examine histological gastric body changes and epithelial cell proliferation before and after treatment with lansoprazole. PATIENTS AND METHODS: Patients diagnosed as having reflux oesophagitis grade 1 or 2 were enrolled and treated for 12 weeks with lansoprazole (30 mg every morning). After 12 weeks, 103 of the 118 patients appeared endoscopically healed and were asymptomatic; they then received maintenance treatment with 15 or 30 mg lansoprazole daily. Biopsy specimens obtained from similar sites before and after treatment, were available from 90 patients after a median of 64 weeks (range 15-73 weeks). Epithelial cell proliferation was determined by the number of Ki-67 antigen positive cells per gland.
RESULTS: Of these 90 patients, 44 (49%) were found to be infected with H pylori. Their median inflammation score had increased from grade 1 before to grade 2 after treatment (p < 0.0001). Initially, the number of Ki-67 antigen positive cells per gland was significantly higher in the H pylori infected than in the uninfected group and increased further after treatment (p < 0.0001). In uninfected patients, no significant change in inflammation or proliferation occurred during treatment.
CONCLUSIONS: A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole. Epithelial cell proliferation and atrophy also increased in infected but not in uninfected patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9462205      PMCID: PMC1891604          DOI: 10.1136/gut.41.6.740

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  39 in total

1.  New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope.

Authors:  G Key; M H Becker; B Baron; M Duchrow; C Schlüter; H D Flad; J Gerdes
Journal:  Lab Invest       Date:  1993-06       Impact factor: 5.662

2.  Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.

Authors:  K Vetvik; E Schrumpf; P Mowinckel; S Aase; K J Andersen
Journal:  Scand J Gastroenterol       Date:  1994-11       Impact factor: 2.423

3.  Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype.

Authors:  J E Crabtree; A Covacci; S M Farmery; Z Xiang; D S Tompkins; S Perry; I J Lindley; R Rappuoli
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

4.  The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens.

Authors:  D McCormick; C Yu; C Hobbs; P A Hall
Journal:  Histopathology       Date:  1993-06       Impact factor: 5.087

5.  Cell proliferation in the gastric corpus in Helicobacter pylori associated gastritis and after gastric resection.

Authors:  D A Lynch; N P Mapstone; A M Clarke; P Jackson; M F Dixon; P Quirke; A T Axon
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

6.  Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy.

Authors:  D A Lynch; N P Mapstone; A M Clarke; G M Sobala; P Jackson; L Morrison; M F Dixon; P Quirke; A T Axon
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

7.  Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.

Authors:  R P Logan; M M Walker; J J Misiewicz; P A Gummett; Q N Karim; J H Baron
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

8.  Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.

Authors:  E C Klinkenberg-Knol; H P Festen; J B Jansen; C B Lamers; F Nelis; P Snel; A Lückers; C P Dekkers; N Havu; S G Meuwissen
Journal:  Ann Intern Med       Date:  1994-08-01       Impact factor: 25.391

9.  Accelerated gastric epithelial proliferation.

Authors:  M R Gray; S J Darnton; J A Hunt; R W Irlam; J Nemeth; H M Wallace
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

10.  Comparison of labelling by bromodeoxyuridine, MIB-1, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens.

Authors:  D A Lynch; A M Clarke; P Jackson; A T Axon; M F Dixon; P Quirke
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

View more
  15 in total

1.  Effect of Helicobacter pylori infection on gastric epithelial cell proliferation.

Authors:  Hong Gao; Ji-Yao Wang; Xi-Zhong Shen; Jian-Jun Liu
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

Review 2.  Inflammation, atrophy, and gastric cancer.

Authors:  James G Fox; Timothy C Wang
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.

Authors:  Marinko Marusic; Zarko Babic; Mirjana Nesanovic; Mira Lucijanic-Mlinac; Vesna Stajcar
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 4.  A benefit-risk assessment of the use of proton pump inhibitors in the elderly.

Authors:  Gwen M C Masclee; Miriam C J M Sturkenboom; Ernst J Kuipers
Journal:  Drugs Aging       Date:  2014-04       Impact factor: 3.923

Review 5.  Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review.

Authors:  Anan Raghunath; A Pali S Hungin; David Wooff; Susan Childs
Journal:  BMJ       Date:  2003-04-05

Review 6.  Gastric atrophy, diagnosing and staging.

Authors:  Hala M T El-Zimaity
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

7.  No protective role of Helicobacter pylori in the pathogenesis of reflux esophagitis in patients with duodenal or benign gastric ulcer in Korea.

Authors:  N Kim; S H Lim; K H Lee
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

8.  Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.

Authors:  B E Schenk; E J Kuipers; G F Nelis; E Bloemena; J C Thijs; P Snel; A E Luckers; E C Klinkenberg-Knol; H P Festen; P P Viergever; J Lindeman; S G Meuwissen
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

9.  Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.

Authors:  E J Kuipers; G F Nelis; E C Klinkenberg-Knol; P Snel; D Goldfain; J J Kolkman; H P M Festen; J Dent; P Zeitoun; N Havu; M Lamm; A Walan
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes.

Authors:  Soumana C Nasser; Mahmoud Slim; Jeanette G Nassif; Selim M Nasser
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.